Anbio Biotechnology (NNNN) Accumulated Expenses (2023 - 2025)

Anbio Biotechnology has reported Accumulated Expenses for 3 years, with the latest figure at $87836.0 in Q4 2025.

• On a quarterly basis, Accumulated Expenses fell 16.33% year-over-year to $87836.0 in Q4 2025; TTM through Dec 2025 was $87836.0, a 16.33% decrease from a year earlier, with the FY2025 full-year figure at $87836.0, down 16.33% from the prior year.
• Accumulated Expenses was $87836.0 for Q4 2025 at Anbio Biotechnology, down from $104979.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $130967.0 in Q4 2023, with the low at $87836.0 in Q4 2025.
• Average Accumulated Expenses over 3 years is $107927.3, with a median of $104979.0 recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses fell 19.84% in 2024, then slipped 16.33% in 2025.
• Over 3 years, Accumulated Expenses stood at $130967.0 in 2023, then slipped by 19.84% to $104979.0 in 2024, then decreased by 16.33% to $87836.0 in 2025.
• The last three Accumulated Expenses figures came in at $87836.0 (Q4 2025), $104979.0 (Q4 2024), and $130967.0 (Q4 2023), per Business Quant data.